Four biotech companies from South Korea announced new or planned financings mid-June, including GC Genome Corp. Rznomics Inc., G2Gbio Inc. and Mezzion Pharma Co. Ltd. Six major mid-June deals included ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.

Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene therapy to treat hereditary hearing loss.

Navigating healthcare is challenging for most individuals and families, but for those facing rare or chronic conditions, the obstacles can feel even more overwhelming. They often encounter delayed ...

Anumana’s ECG-AI platform includes a suite of algorithms designed to detect cardiovascular diseases that are challenging to detect without costly, invasive, or difficult-to-access clinical tests. The ...

Phase II results for Cybin’s psilocin therapy showed remission rates of 71%, but just eight patients made it to the 12-month milestone.

CEVEC Pharmaceuticals GmbH and Rznomics Inc. have signed a clinical and commercial license agreement for the use of CEVEC’s CAP Technology for the manufacture of adenoviruses for gene therapy ...